PharmaPendium Metabolizing Enzymes and Transporters Module is available now; for more information go to: http://www.elsevier.com/pharmapendium
PharmaPendium decision support tool allows safety assessment teams, toxicologists, pharmacokineticists and project leaders to extract relevant comparative pharmacological and pharmacokinetic information from the entire history of drug development by locating published regulatory and commercial precedents sharing similarities with the class, the target or the structural chemistry of candidate drugs. This allows R&D organizations to make faster, more reliable decisions about which candidate compounds to take forward to pre-clinical phases.
PharmaPendium® and the PharmaPendium® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including
, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include
, which enhance the productivity of science and health professionals, and the
MEDai's Pinpoint Review
, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in
employs 7,000 people worldwide. The company is part of
Reed Elsevier Group plc
, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in
. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the
and New York Stock Exchanges using the following ticker symbols:
: RUK and ENL.